keyword
MENU ▼
Read by QxMD icon Read
search

fish for breast disease

keyword
https://www.readbyqxmd.com/read/27895501/a-fish-based-method-for-assessment-of-her-2-amplification-status-in-breast-cancer-circulating-tumor-cells-following-cellsearch-isolation
#1
Henrik Frithiof, Kristina Aaltonen, Lisa Rydén
INTRODUCTION: Amplification of the HER-2/neu (HER-2) proto-oncogene occurs in 10%-15% of primary breast cancer, leading to an activated HER-2 receptor, augmenting growth of cancer cells. Tumor classification is determined in primary tumor tissue and metastatic biopsies. However, malignant cells tend to alter their phenotype during disease progression. Circulating tumor cell (CTC) analysis may serve as an alternative to repeated biopsies. The Food and Drug Administration-approved CellSearch system allows determination of the HER-2 protein, but not of the HER-2 gene...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27893937/prognostic-significance-of-equivocal-human-epidermal-growth-factor-receptor-2-results-and-clinical-utility-of-alternative-chromosome-17-genes-in-patients-with-invasive-breast-cancer-a-cohort-study
#2
Nour Sneige, Kenneth R Hess, Asha S Multani, Yun Gong, Nuhad K Ibrahim
BACKGROUND: The 2013 testing guidelines for determining the human epidermal growth factor receptor 2 (HER2) status include new cutoff points for the HER2/chromosome enumeration probe 17 (CEP17) ratio and the average HER2 copy number per cell, and they recommend using a reflex test with alternative chromosome 17 probes (Ch17Ps) to resolve equivocal HER2 results. This study sought to determine the clinical utility of alternative Ch17Ps in equivocal cases and the effects of equivocal results and/or a change in the HER2 status on patients' outcomes...
November 28, 2016: Cancer
https://www.readbyqxmd.com/read/27864894/maternal-dietary-intake-in-pregnancy-and-lactation-and-allergic-disease-outcomes-in-offspring
#3
REVIEW
Carina Venter, Kari R Brown, Kate Maslin, Debra J Palmer
As the prevalence of allergic disease dramatically rises worldwide, prevention strategies are increasingly being considered. Given the potential modulatory effect of nutritional factors on disease, altering maternal diet during pregnancy and/or lactation has been considered in preventing allergic disease in offspring. Though there are a number of observational studies that have examined possible associations between maternal diet and allergic outcomes in offspring, interventional trials are limited. Furthermore, there is a paucity of studies that have prospectively studied maternal dietary intake as well as measuring maternal and infant biological samples (blood, urine, breast milk) and their relation to allergic outcomes in infants...
November 19, 2016: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/27861897/genome-evolution-in-ductal-carcinoma-in-situ-invasion-of-the-clones
#4
REVIEW
Anna Casasent, Mary Edgerton, Nicholas E Navin
Ductal Carcinoma In Situ (DCIS) is the most frequently diagnosed early stage breast cancer. Only a subset of patients progress to invasive ductal carcinoma (IDC), and this presents a formidable clinical challenge for determining which patients to treat aggressively and which patients to monitor without therapeutic intervention. Understanding the molecular and genomic basis of invasion has been difficult to study in DCIS cancers due to several technical obstacles, including low tumour cellularity, lack of fresh-frozen tissues, and intratumour heterogeneity...
November 9, 2016: Journal of Pathology
https://www.readbyqxmd.com/read/27835607/p16-overexpression-and-9p21-deletion-are-linked-to-unfavorable-tumor-phenotype-in-breast-cancer
#5
Patrick Lebok, Magdalena Roming, Martina Kluth, Christina Koop, Cansu Özden, Berivan Taskin, Khakan Hussein, Annette Lebeau, Isabell Witzel, Linn Wölber, Stefan Geist, Peter Paluchowski, Christian Wilke, Uwe Heilenkötter, Volkmar Müller, Barbara Schmalfeldt, Ronald Simon, Guido Sauter, Luigi Terracciano, Rainer Horst Krech, Albert von der Assen, Eike Burandt
Overexpression of the p16 tumor suppressor, but also deletion of its gene locus 9p21, is linked to unfavorable tumor phenotype and poor prognosis in breast cancer. To better understand these contradictory observations, and to clarify the prognostic impact of p16 expression and 9p21 deletion, a tissue microarray (TMA) with 2,197 breast cancers was analyzed by fluorescence in-situ hybridization and immunohistochemistry (FISH) for 9p21 deletion and p16 expression. p16 immunostaining was weak in 25.6%, moderate in 7...
November 9, 2016: Oncotarget
https://www.readbyqxmd.com/read/27785012/docosahexaenoic-acid-liposomes-for-targeting-chronic-inflammatory-diseases-and-cancer-an-in-vitro-assessment
#6
Amr Alaarg, Nan Yeun Jordan, Johan Jf Verhoef, Josbert M Metselaar, Gert Storm, Robbert J Kok
Inflammation, oxidative stress, and uncontrolled cell proliferation are common key features of chronic inflammatory diseases, such as atherosclerosis and cancer. ω3 polyunsaturated fatty acids (PUFAs; also known as omega3 fatty acids or fish oil) have beneficial effects against inflammation upon dietary consumption. However, these effects cannot be fully exploited unless diets are enriched with high concentrations of fish oil supplements over long periods of time. Here, a nanomedicine-based approach is presented for delivering effective levels of PUFAs to inflammatory cells...
2016: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/27770345/chemosensitivity-and-endocrine-sensitivity-in-clinical-luminal-breast-cancer-patients-in-the-prospective-neoadjuvant-breast-registry-symphony-trial-nbrst-predicted-by-molecular-subtyping
#7
Pat Whitworth, Peter Beitsch, Angela Mislowsky, James V Pellicane, Charles Nash, Mary Murray, Laura A Lee, Carrie L Dul, Michael Rotkis, Paul Baron, Lisette Stork-Sloots, Femke A de Snoo, Jennifer Beatty
PURPOSE: Hormone receptor-positive (HR+) tumors have heterogeneous biology and present a challenge for determining optimal treatment. In the Neoadjuvant Breast Registry Symphony Trial (NBRST) patients were classified according to MammaPrint/BluePrint subtyping to provide insight into the response to neoadjuvant endocrine therapy (NET) or neoadjuvant chemotherapy (NCT). OBJECTIVE: The purpose of this predefined substudy was to compare MammaPrint/BluePrint with conventional 'clinical' immunohistochemistry/fluorescence in situ hybridization (IHC/FISH) subtyping in 'clinical luminal' [HR+/human epidermal growth factor receptor 2-negative (HER2-)] breast cancer patients to predict treatment sensitivity...
October 21, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27748278/evaluation-of-her2-neu-oncoprotein-in-serum-tissue-samples-of-women-with-breast-cancer
#8
Shailaja Shukla, Bhawana Komal Singh, Om Prakash Pathania, Manjula Jain
BACKGROUND & OBJECTIVES: The proto-oncogene HER2/neu has been extensively studied in breast cancer patients. Serum levels of HER2/neu by ELISA in breast cancer patients were compared with tissue HER2/neu expression and with other clinicopathological parameters with the aim to investigate whether the serum assay could replace the established tests (IHC/FISH) for HER-2 status. METHODS: Blood and Tru-cut biopsy samples were collected for determining HER2/neu status in 64 breast cancer patients...
May 2016: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/27739521/label-free-enumeration-collection-and-downstream-cytological-and-cytogenetic-analysis-of-circulating-tumor-cells
#9
Manjima Dhar, Edward Pao, Corinne Renier, Derek E Go, James Che, Rosita Montoya, Rachel Conrad, Melissa Matsumoto, Kyra Heirich, Melanie Triboulet, Jianyu Rao, Stefanie S Jeffrey, Edward B Garon, Jonathan Goldman, Nagesh P Rao, Rajan Kulkarni, Elodie Sollier-Christen, Dino Di Carlo
Circulating tumor cells (CTCs) have a great potential as indicators of metastatic disease that may help physicians improve cancer prognostication, treatment and patient outcomes. Heterogeneous marker expression as well as the complexity of current antibody-based isolation and analysis systems highlights the need for alternative methods. In this work, we use a microfluidic Vortex device that can selectively isolate potential tumor cells from blood independent of cell surface expression. This system was adapted to interface with three protein-marker-free analysis techniques: (i) an in-flow automated image processing system to enumerate cells released, (ii) cytological analysis using Papanicolaou (Pap) staining and (iii) fluorescence in situ hybridization (FISH) targeting the ALK rearrangement...
October 14, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27633145/gata3-expression-in-primary-vulvar-paget-disease-a-potential-pitfall-leading-to-misdiagnosis-of-pagetoid-urothelial-intraepithelial-neoplasia
#10
Diogo Morbeck, Aline C Tregnago, Glauco Baiocchi Netto, Carlos Sacomani, Patricia M Peresi, Cynthia T Osório, Luciana Schutz, Stephania M Bezerra, Louise de Brot, Isabela W Cunha
AIMS: GATA3 has been reported as a specific urothelial marker among organs in the pelvic region, and has been classified as highly sensitive and specific for urothelial and breast carcinomas. Our aim was to verify GATA3 expression in extramammary Paget disease, and to determine whether it can be use to differentiate primary vulvar Paget disease from pagetoid urothelial intraepithelial neoplasia (PUIN). We also analysed HER2 protein expression and HER2 gene amplification and their roles as prognostic factors in extramammary Paget disease...
September 16, 2016: Histopathology
https://www.readbyqxmd.com/read/27632289/use-of-a-multiplexed-immunoassay-pro-onc-assay-to-detect-her2-abnormalities-in-circulating-tumor-cells-of-women-with-her2-negative-metastatic-breast-cancer-lack-of-response-to-her2-targeted-therapy
#11
John D Hainsworth, Patrick B Murphy, Jose R Alemar, Brooke R Daniel, Robyn R Young, Denise A Yardley
PURPOSE: Determination of HER2 status by testing circulating tumor cells (CTCs), compared to sampling tumor biopsies, may improve patient management by allowing ongoing assessment of HER2 status during the disease course. The PRO Onc assay (Prometheus Laboratories; San Diego, CA) is a multiplexed immunoassay that measures the expression and activation of HER2 in CTCs. In this study, we screened patients with metastatic HER2-negative breast cancer with the PRO Onc assay; patients with HER2 overexpression or activation received a trial of HER2-targeted therapy...
November 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27631512/proposal-of-a-provisional-classification-of-sebaceous-carcinoma-based-on-hormone-receptor-expression-and-her2-status
#12
Hee Young Na, Ji-Young Choe, Seon Ah Shin, Ho-Kyung Choung, Sohee Oh, Jin-Haeng Chung, Mira Park, Ji Eun Kim
Despite recent progress in comprehensive genetic analysis, little is known about the molecular pathogenesis of sebaceous carcinoma. On the basis of the ontogenic proximity of sebaceous and mammary glands, we designed an intrinsic classification for sebaceous carcinoma adapted from that of breast cancer and evaluated its clinical significance. We investigated 42 cases of sebaceous carcinoma, including 32 ocular and 10 extraocular cases. Immunohistochemical analyses for estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), HER2, Ki67, and CK5/6 and fluorescence in situ hybridization for the HER2 gene were performed...
September 14, 2016: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/27626701/cdcp1-is-a-novel-marker-of-the-most-aggressive-human-triple-negative-breast-cancers
#13
Federica Turdo, Francesca Bianchi, Patrizia Gasparini, Marco Sandri, Marianna Sasso, Loris De Cecco, Luca Forte, Patrizia Casalini, Piera Aiello, Lucia Sfondrini, Roberto Agresti, Maria Luisa Carcangiu, Ilaria Plantamura, Gabriella Sozzi, Elda Tagliabue, Manuela Campiglio
CDCP1, a transmembrane noncatalytic receptor, the expression of which has been associated with a poor prognosis in certain epithelial cancers, was found to be expressed in highly aggressive triple-negative breast cancer (TNBC) cell models, in which it promoted aggressive activities-ie, migration, invasion, anchorage-independent tumor growth, and the formation of vascular-like structures in vitro. By immunohistochemical (IHC) analysis of 100 human TNBC specimens, CDCP1 was overexpressed in 57% of samples, 38% of which exhibited a gain in CDCP1 copy number by fluorescence in situ hybridization (FISH)...
September 10, 2016: Oncotarget
https://www.readbyqxmd.com/read/27589688/primary-analysis-of-a-prospective-randomized-single-blinded-phase-ii-trial-evaluating-the-her2-peptide-gp2-vaccine-in-breast-cancer-patients-to-prevent-recurrence
#14
Elizabeth A Mittendorf, Alexandros Ardavanis, Jennifer K Litton, Nathan M Shumway, Diane F Hale, James L Murray, Sonia A Perez, Sathibalan Ponniah, Constantin N Baxevanis, Michael Papamichail, George E Peoples
GP2 is a HER2-derived, HLA-A2+ restricted peptide. Phase I studies showed GP2 administered with GM-CSF to be safe and immunogenic. Here we report the primary analysis of a prospective, randomized, multicenter phase II adjuvant trial conducted to determine the vaccine's efficacy. The trial enrolled HLA-A2+, clinically disease-free, node-positive and high-risk node-negative breast cancer patients with tumors expressing HER2 (immunohistochemistry[IHC] 1+-3+). Patients were randomized to GP2+GM-CSF versus GM-CSF alone...
August 31, 2016: Oncotarget
https://www.readbyqxmd.com/read/27573653/her2-gene-amplification-testing-by-fluorescent-in-situ-hybridization-fish-comparison-of-the-asco-college-of-american-pathologists-guidelines-with-fish-scores-used-for-enrollment-in-breast-cancer-international-research-group-clinical-trials
#15
Michael F Press, Guido Sauter, Marc Buyse, Hélène Fourmanoir, Emmanuel Quinaux, Denice D Tsao-Wei, Wolfgang Eiermann, Nicholas Robert, Tadeusz Pienkowski, John Crown, Miguel Martin, Vicente Valero, John R Mackey, Valerie Bee, Yanling Ma, Ivonne Villalobos, Anaamika Campeau, Martina Mirlacher, Mary-Ann Lindsay, Dennis J Slamon
PURPOSE: ASCO and the College of American Pathologists (ASCO-CAP) recently recommended further changes to the evaluation of human epidermal growth factor receptor 2 gene (HER2) amplification by fluorescent in situ hybridization (FISH). We retrospectively assessed the impact of these new guidelines by using annotated Breast Cancer International Research Group (BCIRG) -005, BCIRG-006, and BCIRG-007 clinical trials data for which we have detailed outcomes. PATIENTS AND METHODS: The HER2 FISH status of BCIRG-005/006/007 patients with breast cancers was re-evaluated according to current ASCO-CAP guidelines, which designates five different groups according to HER2 FISH ratio and average HER2 gene copy number per tumor cell: group 1 (in situ hybridization [ISH]-positive): HER2-to-chromosome 17 centromere ratio ≥ 2...
August 29, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27566580/her2-amplification-level-is-not-a-prognostic-factor-for-her2-positive-breast-cancer-with-trastuzumab-based-adjuvant-treatment-a-systematic-review-and-meta-analysis
#16
Qian-Qian Xu, Bo Pan, Chang-Jun Wang, Yi-Dong Zhou, Feng Mao, Yan Lin, Jing-Hong Guan, Song-Jie Shen, Xiao-Hui Zhang, Ya-Li Xu, Ying Zhong, Xue-Jing Wang, Yan-Na Zhang, Qiang Sun
BACKGROUND: Trastuzumab-based therapy is a standard, targeted treatment for HER2-positive breast cancer in the adjuvant setting. However, patients do not benefit equally from it and the association between HER2 amplification level and patients' survival remains controversial. A systematic review and meta-analysis was conducted by incorporating all available evidence to evaluate the association between disease free survival (DFS) and HER2 amplification level. RESULTS: Three cohort studies involving 1360 HER2-positive breast cancer patients stratified by HER2 amplification magnitude were eligible for meta-analysis...
August 23, 2016: Oncotarget
https://www.readbyqxmd.com/read/27563438/continuation-of-trastuzumab-beyond-disease-progression-in-her2-positive-metastatic-gastric-cancer-the-md-anderson-experience
#17
Humaid O Al-Shamsi, Yazan Fahmawi, Ibrahim Dahbour, Aziz Tabash, Jane E Rogers, Jeannette Elizabeth Mares, Mariela A Blum, Jeannelyn Estrella, Aurelio Matamoros, Tara Sagebiel, Catherine E Devine, Brian D Badgwell, Quan D Lin, Prajnan Das, Jaffer A Ajani
BACKGROUND: Despite the wide spread use of trastuzumab in human epidermal growth factor receptor 2 (HER2) overexpressing metastatic gastric cancer patients, its optimal duration of administration beyond first-line disease progression is unknown. In HER2 overexpressing metastatic breast cancer, trastuzumab continuation beyond first-line disease progression has shown improvement in time to progression (TTP) without an increased risk of treatment related toxicity. METHODS: HER2-overexpressing metastatic gastric cancer patients were identified from our database between January 2010 and December 2014...
August 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/27532780/perinatal-consumption-of-thiamine-fortified-fish-sauce-in-rural-cambodia-a-randomized-clinical-trial
#18
Kyly C Whitfield, Crystal D Karakochuk, Hou Kroeun, Daniela Hampel, Ly Sokhoing, Benny B Chan, Mam Borath, Prak Sophonneary, Judy McLean, Aminuzzaman Talukder, Larry D Lynd, Eunice C Y Li-Chan, David D Kitts, Lindsay H Allen, Timothy J Green
Importance: Infantile beriberi, a potentially fatal disease caused by thiamine deficiency, remains a public health concern in Cambodia and regions where thiamine-poor white rice is a staple food. Low maternal thiamine intake reduces breast milk thiamine concentrations, placing breastfed infants at risk of beriberi. Objective: To determine if consumption of thiamine-fortified fish sauce yields higher erythrocyte thiamine diphosphate concentrations (eTDP) among lactating women and newborn infants and higher breast milk thiamine concentrations compared with a control sauce...
October 3, 2016: JAMA Pediatrics
https://www.readbyqxmd.com/read/27530622/assessment-of-her2-status-in-patients-with-gastroesophageal-adenocarcinoma-treated-with-epirubicin-based-chemotherapy-heterogeneity-related-issues-and-prognostic-implications
#19
Nicola Personeni, Marina Baretti, Silvia Bozzarelli, Paola Spaggiari, Luca Rubino, Maria Chiara Tronconi, Uberto Fumagalli Romario, Riccardo Rosati, Laura Giordano, Massimo Roncalli, Armando Santoro, Lorenza Rimassa
BACKGROUND: HER2 and topoisomerase 2 alpha (TOP2A) genomic status was previously reported to predict benefit from anthracyclines in breast cancer. We sought to define the prognostic impact and possible pitfalls related to these biomarkers in resectable gastroesophageal adenocarcinoma. METHODS: HER2 and TOP2A gene amplification by fluorescent in situ hybridization and HER2 protein expression by immunohistochemistry (IHC) were assessed on whole tissue sections from 101 patients receiving peri- or postoperative epirubicin-based chemotherapy...
August 16, 2016: Gastric Cancer
https://www.readbyqxmd.com/read/27478318/efficacy-and-safety-of-trastuzumab-combined-with-chemotherapy-for-first-line-treatment-and-beyond-progression-of-her2-overexpressing-advanced-breast-cancer
#20
Huiping Li, Bin Shao, Yin Yan, Guohong Song, Xiaoran Liu, Jing Wang, Xu Liang
OBJECTIVE: To observe the efficacy and safety of trastuzumab combined with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing advanced breast cancer. METHODS: A total of 90 patients with HER2-overexpressing advanced breast cancer were enrolled in this study. All patients were diagnosed with ductal invasive breast cancer by pathological analysis, and were aged between 31-73 years with a median of 51 years. HER2-positivity was defined as 3(+) staining in immunochemistry or amplification of fluorescence in situ hybridization (FISH, ratio ≥2...
June 2016: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
keyword
keyword
106355
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"